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Abstract
The partial rebreathing method for cardiac output determination produces short periods of elevated arterial CO2 content.
Because previous work had shown that elevated etCO2 levels increased cardiac output, mostly due to heart rate increases,
a concern was raised that the rebreathing periods could be inducing an elevated heart rate. This could also raise the
cardiac output (CO), since CO = (Heart Rate) X (Stroke Volume). We studied 93 patients in the OR and the ICU who
had undergone a total of 5142 partial rebreathing measurements by the NICO2 monitor (Novametrix Medical Systems) to
determine whether the heart rate was raised, even if transiently, during the monitored period. Our conclusion was that the
rebreathing periods caused no detectable change in the heart rate.
expiratory) CO2 levels between the rebreathing and
normal periods is approximately 5 mmHg. It is during
this period of elevated arterial CO2 levels that the
appropriate variables for the cardiac output calculation are
generated. A concern was raised that since the CO2 levels
were being elevated for the measurement, the cardiac
output may have been raised by the measurement
technique itself. This concern was related to previous
work, including that of Eger20, which stated that cardiac
output was raised, mostly due to increased heart rate,
when the etCO2 was raised stepwise in six-minute
increments.

Introduction
Cardiac output is a clinically important variable
although it remains difficult to measure, since it is based
on many interrelated factors and can vary even with
respiration. Information about the level of cardiac output
describes the general health of the heart and
cardiovascular system and can be used by physicians to
guide care, especially in critical care situations. Cardiac
output is monitored clinically in about 1,000,000 patients
each year with the bolus thermodilution technique.1 The
thermodilution method, in which a bolus of cold saline is
injected through a pulmonary artery (PA) catheter directly
into the heart, is currently the most widely used and
clinically accepted standard for measurement of cardiac
output.2,3. Unfortunately, the costs associated with
placement of a PA catheter are high. Because it is
associated with considerable morbidity and mortality, 4-6
not all patients in whom cardiac output monitoring would
be valuable can be monitored by thermodilution.

To address this issue, we monitored 93 subjects in the
OR and the ICU who underwent NICO2 non-invasive
cardiac output monitoring to see if we could observe a
difference in the heart rate attributable to the elevated CO2
levels.
Partial Rebreathing Non-invasive Cardiac Output
Technology (NICO2)

A reliable method for measuring cardiac output noninvasively is desirable, especially for those patients who
are at risk for peri-operative cardiac morbidity but in
whom the risk-benefit ratio does not justify invasive
monitoring. Non-invasive methods are also more
desirable because they can be less costly and can require
less set up time. A number of non-invasive methods have
been introduced for clinical use, including transthoracic
bioimpedance, esophageal Doppler, transesophageal
echocardiography, and NICO2 partial rebreathing.

Our lab has developed a non-invasive CO2
rebreathing system to measure cardiac output from the
respiratory measurements of intubated patients.7,8 The
NICO2 technology has been approved by the FDA and is
commercially available for use in hospitals to monitor
mechanically ventilated patients. Clinical studies have
shown that the NICO2 system performs well in intubated,
mechanically ventilated patients. 25, 26
The method is based on a principle described by
Adolf Fick in 1870.9 Fick postulated that the quantity of a
gas such as O2 or CO2 entering or leaving the lungs is
equal to the quantity of the gas expelled or taken up by the

The NICO2 method is based on a version of the Fick
equation and produces intermittent periods of elevated
arterial CO2 content. The difference in endtidal (or end-

1

lungs per minute and CACO2 and CVCO2 are the alveolar and
mixed venous CO2 contents, respectively. Cardiac output
can be calculated from PCBF by estimating the fraction of
cardiac output bypassing the lung (shunt fraction).

blood as it flows through the pulmonary capillaries and
participates in gas exchange. (Figure 1).
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The alveolar CO2 concentration can be determined
non-invasively by monitoring the endtidal CO2 partial
pressure in the expired gas and relating it to the blood
concentration through a CO2 dissociation curve. Before
inserting the values in the Fick equation, the non-invasive
measurements of CO2 elimination and CACO2 must be
corrected. There are two reasons for this correction. First,
the lung retains some gas, even after complete expiration
(functional residual capacity). Second, some regions of
the lung do not participate in the gas exchange
(deadspace). The NICO2 algorithm can compensate for
these effects.
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Figure 1: Circulation and gas exchange27

To eliminate the need to know mixed venous CO2
content, we use a partial rebreathing technique. A
pneumatically driven valve temporarily adds a serial dead
space to the circuit so that the patient inhales a portion of
the previously exhaled CO2.8,10,11 Partial rebreathing does
not require patient cooperation and has only a small
impact on ventilation. The arterial CO2 content rises in
response to this change in ventilation, and this induced
change is used together with the amount of CO2 produced
to calculate cardiac output.

That is, a mass balance equation can be used to describe
how cardiac output is related to gas exchange. The
conventional Fick technique based on O2 has long been a
standard by which other methods of determining cardiac
output have been evaluated:

Q& =

V&O2 consumed
C aO2 − C v O2

,

V&O2

(1)

The NICO2 system estimates shunt fraction based on
blood oxygen saturation (SpO2) data from the noninvasive pulse oximeter and on concentration of inspired
oxygen (FiO2). The limited accuracy of pulse oximetry
measurements of SpO2 (1-2%) and the steepness of the
oxygen tension-saturation curve (especially for SpO2 >
95%) may lead to inaccuracies in the estimates of noninvasive shunt fraction. In most cases, the shunt fraction
is very small, so even a large relative error in the estimate
of shunt fraction leads to a small error in cardiac output.
An accuracy of up to ± 20% in the estimation of shunt
fraction is sufficient to ensure that the error in the
estimation of cardiac output is less than ±5%.12

& is cardiac output (liters/minute),
where Q

consumed is the
amount of O2 consumed by tissue metabolism
(liters/minute), and C vO2 is the mixed venous O2
concentration of the blood (blood flowing into the
lungs in % volume) and CaO2 is the arterial O2
concentration of blood flowing from the lungs (%volume).
Unfortunately, in its original form, the Fick method is
an invasive method requiring catheterization to determine
the blood gas concentrations (cvO2, caO2 )and VCO2. The
original Fick equation can be modified to require only
non-invasively measured variables21-24. This is done by
expressing the Fick principle in terms of alveolar (A)
instead of arterial (a) blood gas concentrations and by
measuring CO2 elimination rather than O2 uptake:

V&CO2 produced
Q& PCBF =
,
C v CO2 − C ACO2
Q&

Clinical studies have shown that the non-invasive
cardiac output NICO2 system performs well in intubated,
mechanically ventilated patients, in whom regular
breathing patterns and the good seal of the endotracheal
tube provide optimal conditions for the NICO2 system. A
MEDLINE search compared the NICO2 technique with
bioimpedance and Doppler methods. Bias and precision
statistics were used to determine limits of agreement with
thermodilution (two standard deviations of the difference

(2)

where PCBF is the pulmonary capillary blood flow (the part
of the cardiac output actually participating in the gas
exchange), VCO2 is the volume of CO2 excreted by the

Q&

2

from thermodilution / mean cardiac output) for each
method. The proposed NICO2 system showed better
limits of agreement (± 28%) than either impedance (±
37%) or Doppler(± 65%).13-19

with a resolution of 0.1 L/min for flow and 0.1 mmHg for
PCO2. The NICO2 monitor computes and displays VCO2
and PetCO2 data on a breath-to-breath basis. Baseline
values for VCO2 and PetCO2 are calculated as the average
of a group of samples taken 27 seconds before the start of
the rebreathing process. During rebreathing, values for
VCO2 and PetCO2 are calculated as the average of the
samples taken from 25 to 50 seconds into the rebreathing
period.

The NICO2 valve assembly
The NICO2 valve assembly (Figure 2) is connected
between the patient's breathing circuit (at the Y-piece) and
the patient's endotracheal tube. The NICO2 monitor
controls the operation of the pneumatic valve by
application of positive pressure. In its default position,
the pneumatic valve causes gas from the breathing circuit
to bypass the adjustable deadspace. When actuated, the
pneumatic valve places the adjustable deadspace (150-450
ml) serially in the breathing circuit between the Y piece of
the breathing circuit and the endotracheal tube connected
to the patient. This causes the patient to rebreathe a
portion of previously exhaled CO2. The increase in
inhaled CO2 due to rebreathing causes a reduction in the
CO2 volume eliminated from the lung (decrease in VCO2 )
and a corresponding increase in alveolar and arterial CO2
tension (increase in PACO2 and PetCO2).

The changes in PetCO2 and VCO2 are then used to
calculate that part of the cardiac output that participates in
gas exchange (pulmonary capillary blood flow (QPCBF)).
The percentage of cardiac output bypassing the lung
(shunt fraction) is determined based on Nunn's iso-shunt
plots from the inspired O2 fraction (FiO2) values and the
average blood oxygen saturation values (SpO2),
determined non-invasively by a pulse oximeter. Cardiac
output is then calculated from QPCBF and shunt fraction.
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Figure 3:
Typical change in carbon dioxide
elimination and end-tidal CO2 during the rebreathing
cycle.

Figure 2:
The NICO2 valve assembly (Novametrix
Medical Systems)
Methods
The Rebreathing Cycle

Data Collection:

Each NICO2 measurement cycle lasts 3 minutes, and
is comprised of a 60 second baseline period, a 50 second
rebreathing period, and a 70 second recovery period. The
resulting changes in VCO2 and PetCO2 are shown in
Figure 3. The flow and CO2 signals are sampled at 100 Hz

The partial rebreathing cardiac monitor (NICO2,
Novametrix Medical Systems) was used continuously on
93 patients in the OR (n = 50) and the ICU (n = 43). Each
of the patients was intubated and mechanically ventilated
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throughout the measurement period. Patients in the OR
were fully anesthetized under general anesthesia, while
those in the ICU were less deeply anesthetized as they
recovered from surgery. During each of the cases, the
information about the etCO2 and heart rate was
automatically stored on a laptop for later analysis.

Results
A total of 5142 measurement cycles from 50 patients
in the OR and 43 patients in the ICU were examined. In
the OR, an average increase in etCO2 of 5.1 mmHg had a
corresponding average decrease in the heart rate of 0.24
beats/min. The standard deviations were 3.0 mmHg for
etCO2 and 5.5 beats/min for heart rate. The sample and
control groups were found to be statistically different (p<
0.05) from each other for etCO2 but not for HR.

Data Analysis:
Theoretically, the response of the heart rate to the
elevated etCO2 levels could differ according to how
deeply anesthetized the patient is, and therefore the OR
and ICU sample groups were analyzed separately.

In the ICU, and average increase of 7.8 mmHg in
etCO2 levels corresponded to a heart rate decrease of 0.34
beats/min, with standard deviations of 3.1 mmHg and 6.8
beats/min, respectively.

Each recorded three minute rebreathing cycle was
subdivided into 30 six-second intervals. The heart rate
and etCO2 levels recorded during the baseline interval (I0)
were compared to levels before, during, and after the 50
second rebreathing period. For each cycle, differences in
the heart rate and etCO2 were calculated for IDuring or After I0 and I0 – IBefore, where ∆t (seconds) between intervals =
TDA0 and T0B, respectively. To account for the possibility
of underlying trends in the heart rate, the ∆t between the
intervals being compared was set to be equal (TDA0 = T0B).
Thus, for each cycle, there were two resultant ∆HR and
∆etCO2 values with respect to baseline (I0). If the
rebreathing were causing a change in the heart rate, one
would expect to see a difference in HR for IDuring or After - I0
but not for I0 – IBefore .

Discussion
We compared baseline heart rates to rebreathing time
periods and other periods throughout the cycle to examine
whether the heart rate was changed, but did not find
statistically significant differences (at a 0.05 significance
level). The variability in the heart rate was so large that
the standard deviation was much larger than any observed
differences in heart rate. This is an important point
clinically, as some doctors are under the impression that
elevated etCO2 levels produced by the NICO2 could
increase HR.
We observed that the heart rate actually decreased by
less than one beat per minute, but this value was so small
compared to the variability that there is really no change.
This is in contradiction to the results found in the
literature. One explanation for this contradiction could be
that the etCO2 was elevated in our method for only 50
seconds, while in the literature, etCO2 was elevated for six
minutes. During the shorter time period of rebreathing
used by NICO2 we did not observe a difference in heart
rate caused by increases in etCO2 and have concluded that
the concerns related to the possible increases in heart rate
do not affect NICO2 performance.

This process of generating values for ∆HR and
∆etCO2 was repeated for ∆t’s from 14 to 60 seconds while
the I0 was held constant so that the entire 3 minute cycle
period was evaluated. This was done to check whether
there was a delay in the response of the heart rate to
elevated CO2 levels such that it occurred after rebreathing
was completed.
To test whether the differences measured were
significantly different, a second part of the evaluation was
necessary. The same data was again evaluated with the
procedure outlined above, but all intervals occurred
during the baseline (non-rebreathing) period. This set of
data was considered to be the control data which describes
the inherent variation in the respiratory signals and heart
rate during non-rebreathing periods. The student’s t-test
was used to determine whether the sample and control
values were significantly different from one another for
each set of ∆t’s where TDA0sample = TDA0control and T0Bsample
= T0Bcontrol. Standard deviations, averages, and averages
of differences were also calculated.

It was somewhat surprising that the HR did not
change in the ICU patients. This could have been due to
remaining effects of anesthesia or because there is really
no induced change during a short partial rebreathing
period.
This issue should be tested further in
spontaneously breathing, awake subjects.
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